Skip to search formSkip to main contentSkip to account menu

TCH Regimen

Known as: Docetaxel-Carboplatin-Trastuzumab Regimen, Taxotere-Carboplatin-Herceptin Regimen 
A sequential regimen consisting of multiple cycles of docetaxel, carboplatin and trastuzumab, followed by multiple cycles of trastuzumab alone… 
National Institutes of Health

Related topics

Related topics

4 relations
CarboplatinHER2 Positive Breast Carcinomadocetaxeltrastuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial.
621 Background: The combination of docetaxel, carboplatin, and trastuzumab (TCH) is a standard adjuvant and neoadjuvant regimen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)